Primary Biliary Cholangitis and Bile Acid Farnesoid X Receptor Agonists.

chenodeoxycholic acid liver obeticholic acid scaffold ursodeoxycholicacid

Journal

Diseases (Basel, Switzerland)
ISSN: 2079-9721
Titre abrégé: Diseases
Pays: Switzerland
ID NLM: 101636232

Informations de publication

Date de publication:
10 Jun 2020
Historique:
received: 12 05 2020
revised: 04 06 2020
accepted: 05 06 2020
entrez: 14 6 2020
pubmed: 14 6 2020
medline: 14 6 2020
Statut: epublish

Résumé

Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease characterized by the progressive destruction of the intrahepatic bile ducts. Currently, the first line drug for PBC is ursodeoxycholic acid (UDCA) characterized by anti-apoptotic, anti-inflammatory and protective actions on cholangiocytes. Despite its recognized therapeutic action, 30-40% of PBC patients only partially benefit from UDCA therapy. This has led to the identification of the role of the farnesoid x receptor (FXR) in cholestatic liver diseases and, consequently, to the development of obeticholic acid (OCA), a steroid FXR agonist that has been recently approved for the treatment of PBC. OCA though is not effective in all patients and can cause itch, which eventually induces treatment drop out. Therefore, the search for new therapeutic strategies for PBC has begun. This review, in addition to summarizing the current treatments for PBC, provides overview of the chemical characteristics of new steroid FXR agonist candidates that could represent a future perspective for the treatment of PBC.

Identifiants

pubmed: 32532037
pii: diseases8020020
doi: 10.3390/diseases8020020
pmc: PMC7348889
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Références

Nat Rev Gastroenterol Hepatol. 2015 Mar;12(3):147-58
pubmed: 25645973
J Autoimmun. 2019 Jul;101:26-34
pubmed: 31027870
Aliment Pharmacol Ther. 2016 Jan;43(2):283-93
pubmed: 26559762
Hepatology. 2008 Sep;48(3):871-7
pubmed: 18752324
Hepatology. 2015 Aug;62(2):635-43
pubmed: 25678132
Handb Exp Pharmacol. 2019;256:111-136
pubmed: 31161298
J Hepatol. 2015 Apr;62(1 Suppl):S25-37
pubmed: 25920087
Nat Clin Pract Gastroenterol Hepatol. 2006 Jun;3(6):318-28
pubmed: 16741551
Hepatology. 2019 Sep;70(3):788-801
pubmed: 30661255
Lancet Gastroenterol Hepatol. 2017 Oct;2(10):716-726
pubmed: 28818518
Hepatology. 2019 Dec;70(6):2035-2046
pubmed: 30737815
Dig Dis. 2015;33 Suppl 2:94-101
pubmed: 26641264
Hepatol Commun. 2018 Aug 30;2(9):1037-1050
pubmed: 30202819
Hepatol Commun. 2019 May 17;3(8):1085-1097
pubmed: 31388629
N Engl J Med. 2016 Aug 18;375(7):631-43
pubmed: 27532829
Hepatology. 2009 Jul;50(1):291-308
pubmed: 19554543
Lancet. 2015 Oct 17;386(10003):1565-75
pubmed: 26364546
FASEB Bioadv. 2019 Apr 22;1(5):332-343
pubmed: 32123836
Hepatol Res. 2008;38(2):123-31
pubmed: 18034825
J Med Chem. 2005 Aug 25;48(17):5383-403
pubmed: 16107136
J Med Chem. 2016 Oct 13;59(19):9201-9214
pubmed: 27652492
N Engl J Med. 2018 Jun 07;378(23):2171-2181
pubmed: 29874528
Dig Dis Sci. 2016 Oct;61(10):3037-3044
pubmed: 27435324
Pharmaceuticals (Basel). 2018 Oct 11;11(4):
pubmed: 30314377
J Med Chem. 2014 Feb 13;57(3):937-54
pubmed: 24387325
J Hepatol. 2017 Jul;67(1):145-172
pubmed: 28427765
J Autoimmun. 2013 Oct;46:81-7
pubmed: 23871640
J Med Chem. 2006 Jul 13;49(14):4208-15
pubmed: 16821780
Nat Genet. 2010 Aug;42(8):658-60
pubmed: 20639880
J Med Chem. 2002 Aug 15;45(17):3569-72
pubmed: 12166927
J Med Chem. 2014 Oct 23;57(20):8477-95
pubmed: 25247751
Hepatology. 2016 Jul;64(1):189-99
pubmed: 26597786
Genes Immun. 2012 Sep;13(6):461-8
pubmed: 22573116
Hepatol Commun. 2019 Jul 15;3(9):1250-1257
pubmed: 31497745
ACS Med Chem Lett. 2018 Dec 06;10(4):407-412
pubmed: 30996771
Int J Mol Sci. 2018 Jul 16;19(7):
pubmed: 30013008
Clin Pharmacol Drug Dev. 2020 Apr;9(3):395-410
pubmed: 31823525
Int J Mol Sci. 2018 Jul 27;19(8):
pubmed: 30060458
Gastroenterology. 2015 Apr;148(4):751-61.e8
pubmed: 25500425
Sci Rep. 2016 May 19;6:25906
pubmed: 27192935
Hepatology. 2011 Aug;54(2):714-23
pubmed: 21563204
Gastroenterology. 2005 Aug;129(2):476-85
pubmed: 16083704
J Med Chem. 2017 Dec 28;60(24):9960-9973
pubmed: 29148806
Clin Rev Allergy Immunol. 2019 Nov 11;:
pubmed: 31713023
Hepatology. 2014 Oct;60(4):1314-23
pubmed: 24841946
J Med Chem. 2004 Aug 26;47(18):4559-69
pubmed: 15317466

Auteurs

Ludovico Abenavoli (L)

Department of Health Sciences, University "Magna Graecia", 88100 Catanzaro, Italy.

Anna Caterina Procopio (AC)

Department of Health Sciences, University "Magna Graecia", 88100 Catanzaro, Italy.

Sharmila Fagoonee (S)

Institute of Biostructures and Bioimaging (CNR) c/o Molecular Biotechnology Center, 10126 Turin, Italy.

Rinaldo Pellicano (R)

Unit of Gastroenterology, Molinette Hospital, 10126 Turin, Italy.

Marco Carbone (M)

Division of Gastroenterology, Center for Autoimmune Liver Diseases, Department of Medicine and Surgery, University of Milano-Bicocca; 20126 Milan, Italy.
European Reference Network on Hepatological Diseases (ERN RARE-LIVER), San Gerardo Hospital, 20900 Monza, Italy.

Francesco Luzza (F)

Department of Health Sciences, University "Magna Graecia", 88100 Catanzaro, Italy.

Pietro Invernizzi (P)

Division of Gastroenterology, Center for Autoimmune Liver Diseases, Department of Medicine and Surgery, University of Milano-Bicocca; 20126 Milan, Italy.
European Reference Network on Hepatological Diseases (ERN RARE-LIVER), San Gerardo Hospital, 20900 Monza, Italy.

Classifications MeSH